The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

Agency drug reviewers had questioned patient risk criteria and the efficacy endpoint used in a key trial supporting J&J's ...

Johnson & Johnson has won the support of an FDA expert panel in its bid to make Darzalex the first treatment for an early ...

New research, from COMy 2025, has found that specific senescence-associated biomarkers are significantly correlated with ...

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...

GILBERT (AZFamily) — A potential cure for a rare type of blood cancer is currently being used to treat 150 patients at various healthcare centers in the Valley. Details about the medical breakthrough ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Positive feedback was based on Phase III AQUILA trial results, which showed a significant clinical benefit with Darzalex Faspro in patients with high-risk smoldering multiple myeloma.

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.